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(57) 	 ABSTRACT 
A microfluidic device is provided for delivering a drug to an 
individual. The microfluidic device includes a body that 
defines a reservoir for receiving the drug therein. A valve 
interconnects the reservoir to an output needle that is insert-
able into the skin of an individual. A pressure source urges the 
drug from the reservoir toward the needle. The valve is mov-
able between a closed position preventing the flow of the drug 
from the reservoir to the output needle and an open position 
allowing for the flow of the drug from the reservoir to the 
output needle in response to a predetermined condition in the 
physiological fluids of the individual. 
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MICRO-FLUIDIC DEVICE FOR DRUG 
DELIVERY 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a continuation application of parent 
U.S. application Ser. No. 10/762,664, filed Jan. 22, 2004, 
now, U.S. Pat. No. 7,766,902, which is a continuation of U.S. 
application Ser. No. 10/640,345, filed Aug. 13, 2003, now 
abandoned, and entitled "Microfluidic Device For Drug 
Delivery." 
REFERENCE TO GOVERNMENT GRANT 
This invention was made with United States government 
support awarded by the following agencies: NASA NAGS-
1672. The United States has certain rights in this invention. 
FIELD OF THE INVENTION 
This invention relates generally to microfluidic devices, 
and in particular, to a microfluidic device for delivering a 
steady infusion of a drug to an individual. 
BACKGROUND AND SUMMARY OF THE 
INVENTION 
As is known, the pharmaceutical industry has had limited 
success overcoming the challenges of delivering pharmaceu-
ticals to patients. The oral ingestion of pharmaceuticals is 
considered the safest, most convenient and most economical 
method of drug administration. As compared to present alter-
natives, patient acceptance and adherence to a dosing regimen 
is typically higher among orally delivered pharmaceuticals. 
However, the oral delivery of many pharmaceuticals is not 
possible because the pharmaceuticals are either too large or 
too electrically charged to pass through the small intestine to 
reach the bloodstream. In addition, many pharmaceuticals 
that are unable to withstand the environment of the digestive 
tract or to penetrate the dermis need to be injected into the 
patient (e.g. insulin, proteins). As hereinafter described, the 
injection of pharmaceuticals into a patient has certain draw-
backs. 
By way of example, insulin is often used to treat diabetes, 
a disorder of metabolism. Most of the foods eaten by indi-
viduals are broken down in the body into glucose, the form of 
sugar in the blood. Glucose is the main source of fuel for the 
body. After digestion, the glucose passes into the bloodstream 
where it is used by the cells for growth and energy. For 
glucose to get into cells, insulin must be present. Insulin is a 
hormone that is automatically produced by a healthy pancreas 
to move glucose from blood into our cells. In people with 
diabetes, however, the pancreas either produces little or no 
insulin, or the cells do not respond appropriately to the insulin 
that is produced. As a result, glucose builds up in the blood, 
overflows into the urine, and passes out of the body. Conse-
quently, the body loses its main source of fuel, even though 
the blood contains large amounts of glucose. 
In order to use the glucose present in the body, a diabetic 
must take insulin injections every day. The amount of insulin 
taken by an individual must be balanced with the individual's 
food intake and daily activities. Consequently, blood glucose 
levels must be closely monitored through frequent blood glu-
cose checking to insure that blood glucose levels do not fall 
too low or rise too high. When blood glucose levels drop too 
low from certain diabetes medicines —a condition known as 
2 
hypoglycemia —a person can become nervous, shaky, and 
confused. If blood glucose falls, judgment can be impaired 
and a person could faint. Alternatively, a person can also 
become ill if blood glucose levels rise too high, a condition 
5 known as hyperglycemia. Although daily insulin injections 
are a great inconvenience, they are necessary for a diabetics' 
survival. 
Most people with diabetes administer their own insulin 
after learning the proper techniques for insulin preparation 
io and injection. The goal of insulin administration is to give 
enough insulin to cover the amount of food (especially car-
bohydrates) that a person consumes so that blood glucose 
levels remain normal throughout the day and night. It can be 
appreciated that various factors such as the type of insulin 
15 used, the size of the person, the amount, type, and time that 
meals are eaten, and the activity and exercise patterns of the 
person effect the amount of insulin that is required by an 
individual. It takes a dedicated patient to continually monitor 
their blood glucose level and administer the repeated multiple 
20 injections required. Therefore, an autonomous infusion sys-
tem that provides a steady infusion of pharmaceuticals to an 
individual when needed would constitute a significant 
advancement in the art. 
Therefore, it is a primary object and feature of the present 
25 invention to provide a microfluidic device that delivers a 
steady infusion of pharmaceuticals to an individual when 
needed. 
It is a further object and feature of the present invention to 
provide a microfluidic device that delivers a steady infusion 
30 of pharmaceuticals to an individual under autonomous con-
trol. 
It is a still further object and feature of the present invention 
to provide a microfluidic device for delivering a steady infu-
sion of pharmaceuticals to an individual that is simple to 
35 utilize and inexpensive to manufacture. 
In accordance with the present invention, a microfluidic 
device is provided for delivering a drug to an individual. The 
microfluidic device includes a reservoir for receiving a drug 
therein and an output needle. The output needle has an input 
40 in communication with the reservoir and an output receivable 
within the individual. A pressure source is engageable with 
the reservoir for urging the drug from the reservoir through 
the output needle. 
The microfluidic device includes a flexible membrane iso- 
45 lating the pressure source from the reservoir. A valve opera-
tively connects the input of the output needle and the reser-
voir. The valve defines a chamber having an input 
communicating with the reservoir and an output communi-
cating with the input of the output needle. The valve also 
50 includes a flexible membrane dividing the chamber into a first 
drug flow portion and a second trigger receiving portion. A 
trigger is disposed in the trigger receiving portion in the 
chamber of the valve. The trigger has a first configuration 
preventing the flow of the drug through the chamber and a 
55 second configuration allowing for the flow of the drug 
through the chamber. 
A first sensing needle has an input receivable in the indi-
vidual and an output within the trigger receiving portion of 
the chamber. The first sensing needle allows physiological 
60 fluids to pass from the individual to the trigger receiving 
portion of the chamber. A second sensing needle may also be 
provided. The second sensing needle has an input receivable 
in the individual and an output within the trigger receiving 
portion of the chamber. The second sensing needle allows 
65 physiological fluids to pass from the individual to the trigger 
receiving portion of the chamber in the valve. It is contem-
plated for the trigger to include a hydrogel post that i s expand- 
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able in response to exposure to a predetermined condition in 
the physiological fluid. Hydrogels are stimuli crosslinked 
polymeric materials that change their state of swelling, as 
manifested by a change in size, in response to chemical and 
physical changes in their surrounding environment. It is con-
templated for the hydrogel post to be formed entirely from a 
hydrogel material or to be formed from a solid post having the 
hydrogel material formed thereabout. 
The microfluidic device also may include a second reser-
voir for receiving a bolus of the drug therein. An actuation 
device is also provided. The actuation device is movable 
between a non-actuated position and an actuated position 
wherein the bolus of the drug is urged through the outlet 
needle and into the individual. 
In accordance with a further aspect of the present inven-
tion, a microfluidic device is provided for delivering a drug to 
an individual. The microfluidic device includes a body that 
defines a reservoir for receiving the drug therein and a con-
duit. The conduit has an input communicating with the res-
ervoir and an output. An output needle has an input receivable 
in the body to communicate with the output of the conduit and 
an output outside of the body for insertion into the individual. 
A pressure source is engageable with the reservoir for urging 
the drug from the reservoir through the output needle. 
It is contemplated that the output needle be removable from 
the body. In addition, it is contemplated that a flexible mem-
brane isolate the pressure source from the reservoir. The 
conduit may include a valve for controlling the flow of the 
drug from the reservoir to the output needle. The valve defines 
a valve chamber and is movable between a non-actuated 
position wherein the valve prevents the flow of the drug from 
the reservoir to the output needle and an actuated position 
wherein the valve allows for the flow of the drug from the 
reservoir to the output needle. A flexible membrane divides 
the valve chamber into a first drug flow portion and a second 
trigger receiving portion. A trigger is disposed in a trigger 
receiving portion of the valve chamber. The trigger has a first 
configuration with the valve in the non-actuated position and 
a second configuration with the valve in the actuated position. 
A first sensing needle has an input receivable in the individual 
and an output within the trigger receiving portion of the valve 
chamber. The first sensing needle allows physiological fluids 
to pass from the individual to the trigger receiving portion of 
the valve chamber. The trigger includes a hydrogel post. The 
hydrogel post changes the configuration in a response to 
exposure to a predetermined condition in the physiological 
fluids. 
The body may also define a second reservoir for receiving 
a bolus of the drug therein. An actuation device is also pro-
vided. The actuation device moves between a non-actuated 
position and an actuated position wherein the bolus of the 
drug is urged from the second reservoir; through the outlet 
needle; and into the individual. 
In accordance with a still further aspect of the present 
invention, a microfluidic device is provided for delivering a 
drug to an individual. The microfluidic device includes a body 
defining a reservoir for receiving the drug and an output 
needle. The output needle has an input in communication 
with the reservoir and an output receivable within the indi-
vidual. An adhesive is provided for affixing the body to the 
individual. 
The microfluidic device may also include a pressure source 
engageable with the reservoir for urging the drug from the 
reservoir through the output needle. A docketing station sup-
ports the output needle. The docketing station is removably 65 
connected to the body. A valve defining a chamber intercon-
nects the reservoir and the output needle. The valve is mov- 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
Referring to FIGS. 1-4, a microfluidic device in accordance 
with the present invention is generally designated by the 
4 
able between a non-actuated position wherein the valve pre-
vents the flow of the drug from the reservoir to the output 
needle and an actuated position wherein the valve allows for 
the flow of the drug from the reservoir to the output needle. 
5 The valve includes a flexible membrane for dividing the valve 
chamber into a first drug flow portion and a second trigger 
receiving portion. A trigger is positioned within the trigger 
receiving portion of the valve chamber. The trigger has a first 
configuration with the valve in a non-actuated position and a 
second configuration with the valve in the actuated position. 
10 A first sensing needle has an input receivable in the individual 
and an output within the trigger receiving portion of the valve 
chamber. The first sensing needle allows physiological fluids 
to pass from the individual to the trigger receiving portion of 
the valve chamber. The trigger may include a hydrogel post 
15 that changes configuration in response to exposure to a pre-
determined condition in the physiological fluids. 
The body may also define a second reservoir for receiving 
a bolus of the drug therein. An actuation device is also pro-
vided. The actuation device is movable between a non-actu- 
2o ated position and an actuated position wherein the bolus of the 
drug is urged from the second reservoir, through the outlet 
needle, and into the individual. 
BRIEF DESCRIPTION OF THE DRAWINGS 
25 
The drawings furnished herewith illustrate a preferred con-
struction of the present invention in which the above advan-
tages and features are clearly disclosed as well as other which 
will be readily understood from the following description of 
the illustrated embodiments. 
30 	 In the drawings: 
FIG. 1 is a schematic, cross-sectional view showing a first 
embodiment of a microfluidic device in accordance with the 
present invention; 
FIG. 2 is a schematic, cross-sectional view of the microf- 
35 luidic device of FIG. 1 with the valve in a closed position; 
FIG. 3 is a schematic, cross-sectional view of the microf-
luidic device of FIG.1 showing the triggering of the pressure 
source; 
FIG. 4 is a schematic, cross-sectional view showing the 
40 microfluidic device of FIG. 1 with the valve in an open posi-
tion; 
FIG. 5 is a top plan view showing an alternate embodiment 
of a microfluidic device in accordance with the present inven-
tion and a torso to which a microfluidic device may be affixed; 
45 	 FIG. 6 is a schematic, cross-sectional view of the microf- 
luidic device of FIG. 5 with the reservoir thereof empty; 
FIG. 7 is a schematic, cross-sectional view of the microf-
luidic device of FIG. 5 with the reservoir filled with a drug; 
FIG. 8 is a schematic, cross-sectional view of the microf- 
50 luidic device of FIG. 5 showing the drug being dispensed; 
FIG. 9 is a third embodiment of a microfluidic device in 
accordance with the present invention; 
FIG. 10 is an enlarged, schematic view showing the valve 
of the microfluidic device of FIG. 9 in an open position; 
55 FIG. 11 is a schematic, cross-sectional view showing the 
valve ofthe microfluidic device of FIG. 9 in a closedposition; 
FIG. 12 is a schematic, cross-sectional view showing a 
fourth embodiment of the microfluidic device of the present 
invention; and 
60 	 FIG. 13 is a schematic, cross-sectional view of the microf- 
luidic device of FIG. 12 dispensing a drug. 
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reference numeral 10. Microfluidic device 10 includes body 	 prevent drug 16 from flowing from reservoir 14 to outlet 
12 formed from polydimethylsiloxane (PDMS) or the like in 	 needle 34. In other words, valve 28 is in the closed position. 
any conventional manner such as by compression micro- 	 Hydrogel pressure sources 50 are triggered so as to expand, 
molding or rapid prototyping. Body 12 defines reservoir 14 
	
FIG. 3, generating pressure on drug 16 within reservoir 14 in 
for the receiving and the storage of drug 16 therein. Reservoir 5 body 12. The pressure generated by hydrogel pressure 
14 includes output 18 that communicates with input 20 of 	 sources 50 urges drug 16 into flow conduit 22 toward valve 
flow conduit 22. Output 24 of flow conduit 22 communicates 	 28. 
with the input 26 of valve 28. Output 30 of valve 28 commu- 	 As heretofore described, hydrogel trigger 42 is responsive 
nicates with input 32 of outlet needle 34 that projects from 	 to a predetermined condition within the physiological fluid 
body 12. Outlet needle 34 includes outlet end 36 that is io flowing into trigger receiving portion 40 of the valve chamber 
injectable into an individual, as hereinafter described. 	 of valve 28 through sensing needles 44. By way of example, 
Valve 28 includes a valve chamber defined by drug flow 	 it is contemplated that hydrogel trigger 42 shrink in response 
portion 38 and trigger receiving portion 40. Drug flow portion 	 to a predetermined concentration of glucose in the physi- 
38 and trigger receiving portion 40 of the valve chamber 	 ological fluid and that drug 16 within reservoir 14 be insulin. 
within valve 28 are isolated from each other by flexible mem-  15 Upon the sensing of a predetermined concentration of glu- 
brane 41. As is conventional, valve 28 is movable between a 	 cose in the physiological fluid, hydrogel trigger 42 begins to 
closed position, FIGS. 2-3, wherein drug 16 is prevented from 	 shrink. As hydrogel trigger 42 within trigger receiving por- 
flowing through drug flow portion 38 of valve 28 to outlet 	 tion 40 of the valve chamber of valve 28 shrinks, flexible 
needle 34 and an open position, FIGS.1 and 4, wherein drug 	 membrane 41 is withdrawn from input 26 of valve 28 so as to 
16 is free to flow through drug flow portion 38 of valve 16 to 20 open valve 28. As a result, drug 16 is allowed to flow through 
outlet needle 34. 	 drug flow portion 38 of the valve chamber of valve 28 into and 
Hydrogel trigger 42 is positioned within trigger receiving 	 through outlet needle 34, FIG. 4. With valve 28 in the open 
portion 40 of the valve chamber within valve 28. Hydrogels 	 position, FIG. 4, hydrogel pressure sources 50 continue to 
are stimuli crosslinked polymeric materials that change their 	 expand thereby urging flexible membrane 48 into reservoir 14 
state of swelling, as manifested by a change in size, in 25 so as to urge the drug 16 therefrom. As described, drug 16 
response to chemical and physical changes in their surround- 	 flows from reservoir 14 through flow conduit 22; through 
ing environment. In the present invention, hydrogel trigger 42 
	
drug flow portion 38 of the valve chamber in valve 28; 
is sensitive to a predetermined condition within the physi- 	 through outlet needle 34; and into the individual. 
ological fluids received in trigger receiving chamber 40 of the 	 In the event that the glucose level of the physiological fluid 
valve chamber within valve 28. In the disclosed embodiment, so received within trigger receiving portion 40 of the valve 
hydrogel trigger 42 shrinks in response to exposure to the 	 chamber in valve 28 drops below a predetermined level, 
predetermined condition within the physiological fluids. 	 hydrogel trigger 42 will once again expand so as to urge 
However, it can be appreciated that hydrogel trigger 42 may 	 flexible membrane 41 against input 26 to valve 28, thereby 
expand in response to such condition if so desired. 	 closing valve 28. As a result, the flow of drug 16 to the 
The valve 28 further includes a plurality of sensing needles 35 individual is stopped. 
44 extending between trigger receiving portion 40 of the 	 Referring to FIG. 5, an alternate embodiment of a microf- 
valve chamber within valve 28 and the environment outside 	 luidic device in accordance with the present invention is 
body 12. Sensing needles 44 may take the form of an array of 	 generally designated by the reference numeral 60. Similar to 
micro-needles or a single needle similar to outlet needle 34. 	 microfluidic device 10, it is intended that microfluidic device 
Sensing needles 44 allow physiological fluids to flow into 40 60 be affixed to the skin of individual 62. Microfluidic device 
trigger receiving portion 40 of the valve chamber within valve 	 60 includes body 64 that defines reservoir 66 for receiving 
28, for reasons hereinafter described. 	 drug 68 therein. In addition, body 64 defines a pressure source 
Microfluidic device 10 further defines pressure source cav- 	 cavity 70 for receiving a plurality of pressure sources 72, as 
ity 46 that is isolated from reservoir 14 by flexible membrane 	 hereinafter described. In addition, trigger 74 is positioned 
48. A plurality of hydrogel pressure sources 50 are spatially 45 within the pressure source cavity 70 in body 64 of microflu- 
disposed within pressure source cavity 46. Hydrogel pressure 	 idic device 60. Ports 76 and 78 are provided in body 64 to 
sources 50 are responsive to a trigger such as a buffer solution 	 allow communication with reservoir 66 and pressure source 
injectable into pressure source cavity 46 either during or after 	 cavity 70, respectively, with a syringe or the like. 
fabrication of body 12. In the depicted embodiment, the 	 Reservoir 66 and pressure source cavity 70 are separated 
buffer solution injected into pressure source cavity 46 and 5o by first flexible membrane 80. In addition, pressure source 
body 12 causes hydrogel pressure sources 50 to expand and 	 cavity 72 is isolated from input 82 of needle 84 by second 
exert a pressure on flexible membrane 48, for reasons here- 	 flexible membrane 86. Second flexible membrane 86 is 
inafter described. 	 biased over input 82 to outlet needle 84 by trigger 74, as 
In operation, microfluidic device 10 is positioned adjacent 	 hereinafter described. Outlet needle 84 also includes output 
the skin of an individual and urged therein such that input 36 55 88 that is receivable within the skin of an individual 62 
of outlet needle 34 communicates with the subcutaneous 	 In operation, reservoir 66 is filed with drug 68 through port 
layer of the skin of an individual. Sensing needles 44 are of 
	
76 in body 64. Thereafter, body 64 is positioned against the 
sufficient depth within the skin of the individual such that 	 skin of individual 62 such that output 88 of outlet needle 84 
physiological fluids may flow into trigger receiving portion 	 communicates with the subcutaneous layer of the skin. In 
40 of the valve chamber within valve 28. Adhesive 52 is 60 order to trigger operation of microfluidic device 60, buffer 
provided along the lower surface 54 of body 12 so as to affix 	 solution 98 is injected into pressure source cavity 70 through 
microfluidic device 10 to the outer surface of the skin of the 	 port 78 in body 64, FIG. 7. With buffer solution 98 within 
individual. 	 pressure source cavity 70, pressure sources 72 expand in 
In its initial configuration, FIGS. 2-3, hydrogel trigger 42 	 response thereto. Simultaneously, trigger 74 begins to shrink. 
within trigger receiving portion 40 of the valve chamber of the 65 As trigger 74 shrinks, second flexible membrane 86 is with- 
valve 28 urges flexible membrane 41 over input 26 to drug 	 drawn from input 82 of outlet needle 84 such that reservoir 66 
flow portion 38 of the valve chamber within valve 28 so as to 	 is in communication with input 82 of outlet needle 84. As a 
US 8,628,517 B2 
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result, as pressure sources 72 continue to expand, first flexible 
membrane 80 is urged into reservoir 66 causing drug 68 to 
flow from reservoir 66 into and through outlet needle 84, FIG. 
8. Pressure sources 72 continue to expand at a constant rate 
over time such that drug 68 is dispensed into the subcutaneous 
layer of the skin of individual 62 at a constant rate over a 
predetermined time period. 
It can be appreciated, that once drug 68 is expunged from 
reservoir 66, buffer solution 98 may be removed from pres-
sure source cavity 70 so as to cause pressure sources 72 and 
trigger 74 to return to their original configuration. If another 
dosage of drug 66 is required, the process may be repeated. 
Referring to FIGS. 9-11, a still further embodiment of a 
microfluidic device in accordance with the present invention 
is generally designated by the reference numeral 100. Microf-
luidic device 100 includes body 102 defining first reservoir 
104 for receiving drug 106 therein. In addition, body 102 
defines second reservoir 108 for receiving a bolus of drug 106 
therein. Flexible membrane 110 overlaps reservoir 108 and 
defines a bistable button, for reasons hereinafter described. 
Second reservoir 108 communicates with outlet needle 112 
through flow conduit 114. 
First reservoir 104 communicates with outlet needle 112 
through valve 116. Valve 116 includes inlet 118 and outlet 
120 that communicates with outlet needle 112. Valve 116 is 
movablebetween a closedposition, FIG. 11, whereinthe drug 
106 is maintained within reservoir 104, FIG. 11, and an open 
position, FIG. 10 wherein drug 106 of reservoir 104 is free to 
flow through valve 116 into outlet needle 112. 
Valve 116 includes drug flow chamber 122 disposed 
between input 118 and output 120 of valve 116 and trigger 
receiving chamber 128. Trigger receiving chamber 128 is 
isolated from drug flow chamber 122 by flexible membrane 
124. Hydrogel trigger 126 is positioned within trigger receiv-
ing chamber 128 of valve 116. Hydrogel trigger 126 has a first 
enlarged configuration, FIG. 11, wherein hydrogel trigger 
126 engages flexible membrane 124 and urges flexible mem-
brane 124 against input 118 to valve 116 such that valve 116 
is in its closed position, and a second retracted configuration, 
FIG. 10, wherein flexible membrane 124 is spaced from input 
118 to valve 116 such that valve 116 is in its open position. 
Valve 116 further includes a plurality of sensing needles 
130 having inputs extending from body 102 of microfluidic 
device 100 and outputs in communication with trigger receiv-
ing chamber 128 of valve 116. It is intended that sensing 
needles 130 allow for the physiological fluids to pass from an 
individual into trigger receiving chamber 128 in valve 116. 
In operation, valve 116 is initially in its closed position, 
FIG. 11, such that drug 106 is unable to flow from reservoir 
104 to output needle 112. Body 102 of microfluidic device 
106 is positioned against the skin of an individual such that 
outlet needle 112 is inserted into and communicates with the 
subcutaneous layer of the skin and such that sensing needles 
130 allow physiological fluids to flow into trigger receiving 
chamber 128 of valve 116. In response to a predetermined 
condition of the physiological fluid flowing into trigger 
receiving chamber 128 of valve 116, hydrogel trigger 126 
retracts from its expanded configuration, FIG. 11, to its 
retracted configuration, FIG. 10, thereby opening valve 116. 
With valve 116 open, drug 106 is free to flow through valve 
116 and into outlet needle 112. As a result, drug 106 flows 
from outlet 132 of outlet needle 112 into the subcutaneous 
layer of skin of the individual. If the predetermined condition 
of the physiological fluid in trigger receiving chamber 128 of 
valve 116 is relieved, hydrogel trigger 126 returns to its 
expanded configuration, FIG. 11, so as to close valve 116. 
8 
With valve 116 in the closed position, drug 106 in reservoir 
104 no longer flows through outlet needle 112 into the indi-
vidual. 
In such circumstances when a bolus of the drug 106 is 
5 immediately needed by the individual, it is contemplated to 
allow the individual to depress flexible membrane 110 
thereby urging drug 106 from second reservoir 108 into flow 
conduit 114. Drug 106 flows through flow conduit 114 and 
outlet needle 112 into the subcutaneous layer of skin of the 
io individual. 
Referring to FIGS. 12 and 13, a still further embodiment of 
the microfluidic device of the present invention is generally 
designated by the reference numeral 140. Microfluidic device 
140 includes docking station 142 and body 144. Body 144 
15 defines reservoir 146 for receiving drug 148 therein. In addi-
tion, body 144 includes pressure source chamber 150 for 
receiving aplurality of hydrogel pressure sources 152 therein. 
Hydrogel pressure sources 152 expand in response to expo-
sure to a predetermined buffer solution. Body 144 further 
20 defines flow conduit 154 which includes inlet 156 communi-
cating with reservoir 146 in body 144 and outlet 158 commu-
nicating with outer surface 160. Pierceable membrane 162 
may be provided in flow conduit 154 to prevent the undesired 
flow of drug 148 from reservoir 146. 
25 	 Docking station 142 includes base 164 extending along a 
first axis and an alignment support 166 extending normal 
thereto. Needle 168 extends through and is supported by base 
164. Needle 168 includes inlet end 170 on first side 172 of 
base 164 and outlet end 174 on second side 176 of base 164. 
30 It is contemplated to provide an adhesive on second side 176 
of base 164 for affixing docking station 142 to the skin of an 
individual. 
In operation, body 144 is positioned against first side 172 
of base 164 such that inlet end 170 of needle 168 extends into 
35 flow conduit 154 in body 144 through outlet end 158 thereof. 
It is intended that inlet end 170 of needle 168 of docking 
station 142 pierce membrane 162 within flow conduit 154 so 
as to allow drug 148 to flow into and through needle 168. 
Alignment wall 166 of docking station 142 facilitates the 
4o alignment of body 144 on first side 172 of base 164 of docking 
station 142. 
With body 144 mounted on docking station 142, microflu-
idic device 140 is positioned against the skin of an individual 
such that needle 168 pierces the skin and outlet end 174 of 
45 needle 168 is in communication with the subcutaneous layer 
of the skin. Thereafter, a buffer solution is injected into pres-
sure source chamber 150 within body 144 so as to cause 
hydrogel pressure sources 152 to expand. As hydrogel pres-
sure sources 152 expand, flexible membrane 153 is urged into 
5o reservoir 146. As a result, drug 148 is forced from reservoir 
146 through needle 168 into the subcutaneous layer of the 
skin of the individual. Once drug 148 has been dispensed 
from reservoir 146, body 144 may be removed from the 
docking station 142. Thereafter, a replacement body 144 hav- 
55 ing a full dosage of drug 148 in the reservoir 146 may be 
repositioned on docking station 142, as hereinafter described, 
and the process repeated. As described, needle 168 remains 
within the individual thereby reducing the frequency that the 
individual must insert a needle into his skin. 
60 Various modes of carrying out the invention are contem-
plated as being within the scope of the following claims 
particularly pointing out and distinctly claiming the subject 
matter which is regarded as the invention. 
65 	 We claim: 
1. A microfluidic device for deliverying a drug to an indi-
vidual, comprising: 
US 8,628,517 B2 
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a body defining a single, undivided, chamber having a fluid 
impermeable boundary defining the entirety of the 
chamber and including a fluid impermeable membrane 
having a first side partially defining the fluid imperme-
able boundary of the chamber, a second side partially 
defining a reservoir, and fluidically isolating the reser-
voir from the chamber, the chamber being puncturable 
and having an initial state wherein the fluid impermeable 
boundary is unpenetrated; 
an output needle having an input in communication with 
the reservoir and an output receivable within the indi-
vidual; 
an aqueous solution selectively movable between a first 
position external of the chamber and a second position 
within the chamber of the body, the aqueous solution 
being selectively injected into the chamber through the 
fluid impermeable boundary; 
an adhesive for affixing the body to the individual; 
a pressure source including an hydrogel member received 
within the chamber and being expandable in response to 
communication with the aqueous solution deposited in 
the chamber, the hydrogel member engageable with the 
reservoir and urging the drug under pressure from the 
reservoir, through the output needle as the hydrogel 
member expands; and 
a valve interconnecting the reservoir and the output needle, 
the valve movable between a non-actuated position 
wherein the valve prevents the flow of the drug from the 
reservoir to the output needle and an actuated position 
wherein the valve allows for the flow of the drug from the 
reservoir to the output needle. 
2. A microfluidic device for delivering a drug to an indi-
vidual, comprising: 
a body defining a single, undivided chamber having a fluid 
impermeable boundary defining the entirety of the 
10 
chamber and including a fluid impermeable membrane 
having a first side partially defining the fluid imperme-
able boundary of the chamber and a second side partially 
defining a reservoir for receiving the drug and fluidically 
5 isolating the reservoir from the chamber, the chamber 
being puncturable and having an initial state wherein the 
fluid impermeable boundary is unpenetrated; 
an output needle having an input in communication with 
the reservoir and an output receivable within the indi-
go vidual; 
an aqueous solution having a predetermined condition and 
being movable between a first position external of the 
chamber and a second position within the chamber, the 
aqueous solution being selectively deposited into the 
15 chamber of the body through the fluid impermeable 
boundary; 
an adhesive for affixing the body to the individual; 
a pressure source including an hydrogel member posi-
tioned in the chamber and being expandable in response 
20 to exposure to the predetermined condition of the aque-
ous solution being selectively deposited into the cham-
ber, the hydrogel member engageable with the reservoir 
and urging the drug under pressure from the reservoir 
through the output needle as the hydrogel member 
25 	 expands; and 
a valve interconnecting the reservoir and the output needle, 
the valve movable between a non-actuated position 
wherein the valve prevents the flow of the drug from the 
reservoir to the output needle and an actuated position 
30 wherein the valve allows for the flow of the drug from the 
reservoir to the output needle. 
3. The microfluidic device of claim 2 wherein the aqueous 
solution is selectively deposited in the chamber by injection. 
